跳到正文

公司

Vaxcyte

Vaxcyte 的结构

Vaxcyte

公司

4 个关联
上游供应与依赖
自有产品与技术
同行竞争与合作
关系出现时间2026
Vaxcyte公司 · 4 个关联
第 1 层

上游供应与依赖1

同行竞争与合作2

自有产品与技术1

关系

箭头表示关系方向,可按业务类别筛选。

显示第 1 至 6 条,共 6 条

结论

结合来源阅读结论,展开条目查看证据。

事实证据 2

Vaxcyte is re-engineering the way highly complex vaccines are made through XpressCF®, its cell-free protein synthesis platform

GlobeNewswire public company news · 2026-10-07 10:48

查看证据
  • 公司披露GlobeNewswire public company news2026-10-07 10:48
    Vaxcyte is re-engineering the way highly complex vaccines are made through XpressCF®, its cell-free protein synthesis platform
    查看来源
  • 公司披露GlobeNewswire public company news2026-10-07 10:48
    Vaxcyte’s system for producing difficult-to-make proteins and antigens is intended to develop and deliver high-fidelity vaccines
    查看来源
事实证据 1
expected gross proceeds from common stock and pre funded warrants offeringapproximately $500 million USD

The aggregate gross proceeds to Vaxcyte from the common stock and pre-funded warrants offering are expected to be approximately $500 million

GlobeNewswire public company news · 2026-10-07 10:48

查看证据
  • 公司披露GlobeNewswire public company news2026-10-07 10:48
    The aggregate gross proceeds to Vaxcyte from the common stock and pre-funded warrants offering are expected to be approximately $500 million
    查看来源
事实证据 1
expected gross proceeds from notes offering$500 million USD

the aggregate gross proceeds to Vaxcyte from the notes offering are expected to be $500 million

GlobeNewswire public company news · 2026-10-07 10:48

查看证据
  • 公司披露GlobeNewswire public company news2026-10-07 10:48
    the aggregate gross proceeds to Vaxcyte from the notes offering are expected to be $500 million
    查看来源
事实证据 2
产出VAX-31

暂无可公开的证据摘要。

BioPharma Dive · STAT · 2026-10-05 21:52

查看证据
事实证据 1
market value12 billion

暂无可公开的证据摘要。

BioPharma Dive · 2026-10-05 21:52

查看证据
事实证据 2
竞争Pfizer

暂无可公开的证据摘要。

BioPharma Dive · STAT · 2026-10-05 21:52

查看证据

显示第 1 至 6 条,共 9 条

市场与估值

估值数据需要 Pro 或 Research。

升级到 Pro 解锁

暂无: 公司信号 · 财务数据 · 披露文件 · 业绩指引